Analyst Vik Chopra of Wells Fargo reiterated a Buy rating on Enovis (ENOV – Research Report), with a price target of $59.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vik Chopra has given his Buy rating due to a combination of factors surrounding Enovis’s recent developments. The appointment of Damien McDonald as the new CEO, who brings a wealth of experience from his previous leadership roles in the MedTech and Orthopedic sectors, is expected to resonate positively with investors. His familiarity with business systems akin to Enovis’s own operational strategies is seen as a strategic advantage.
Additionally, Enovis has reiterated its Q1 guidance, projecting strong revenue and EBITDA figures, which align closely with market expectations. The company’s management has expressed confidence in the current market trajectory, supported by robust procedure volumes. These factors collectively contribute to a positive outlook for Enovis, justifying the Buy rating.
Chopra covers the Healthcare sector, focusing on stocks such as Globus Medical, DENTSPLY SIRONA, and Envista Holdings. According to TipRanks, Chopra has an average return of 2.8% and a 39.34% success rate on recommended stocks.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $75.00 price target.